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Abstract: Mavoglurant binds to same allosteric site on metabotropic glutamate receptor 5 (mGluR5) as
[11C]-ABP688, a radioligand. This open-label, single-center pilot study estimates extent of occupancy
of mGluR5 receptors following single oral doses of mavoglurant, using [11C]-ABP688 positron emission
tomography (PET) imaging, in six healthy males aged 20–40 years. This study comprised three periods
and six subjects were divided into two cohorts. On Day 1 (Period 1), baseline clinical data and safety
samples were obtained along with PET scan. During Period 2 (1–7 days after Period 1), cohort 1
and 2 received mavoglurant 25 mg and 100 mg, respectively. During Period 3 (7 days after Period
2), cohort 1 and 2 received mavoglurant 200 mg and 400 mg, respectively. Mavoglurant showed the
highest distribution volumes in the cingulate region with lower uptake in cerebellum and white matter,
possibly because myelinated axonal sheets maybe devoid of mGlu5 receptors. Maximum concentrations of
mavoglurant were observed around 2–3.25 h post-dose. Mavoglurant passed the blood–brain barrier and
induced dose- and exposure-dependent displacement of [11C]-ABP688 from the mGluR5 receptors, 3–4 h
post-administration (27%, 59%, 74%, 85% receptor occupancy for mavoglurant 25 mg, 100 mg, 200 mg,
400 mg dose, respectively). There were no severe adverse effects or clinically significant changes in safety
parameters. This is the first human receptor occupancy study completed with Mavoglurant. It served
to guide the dosing of mavoglurant in the past and currently ongoing clinical studies. Furthermore,
it confirms the utility of [11C]-ABP688 as a unique tool to study drug-induced occupancy of mGlu5
receptors in the living human brain.
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Single oral dose 
a b s t r a c t 
Mavoglurant binds to same allosteric site on metabotropic glutamate receptor 5 (mGluR5) as [ 11 C]-ABP688, a 
radioligand. This open-label, single-center pilot study estimates extent of occupancy of mGluR5 receptors fol- 
lowing single oral doses of mavoglurant, using [ 11 C]-ABP688 positron emission tomography (PET) imaging, in 
six healthy males aged 20–40 years. This study comprised three periods and six subjects were divided into two 
cohorts. On Day 1 (Period 1), baseline clinical data and safety samples were obtained along with PET scan. Dur- 
ing Period 2 (1–7 days after Period 1), cohort 1 and 2 received mavoglurant 25 mg and 100 mg, respectively. 
During Period 3 (7 days after Period 2), cohort 1 and 2 received mavoglurant 200 mg and 400 mg, respectively. 
Mavoglurant showed the highest distribution volumes in the cingulate region with lower uptake in cerebellum and 
white matter, possibly because myelinated axonal sheets maybe devoid of mGlu5 receptors. Maximum concen- 
trations of mavoglurant were observed around 2–3.25 h post-dose. Mavoglurant passed the blood–brain barrier 
and induced dose- and exposure-dependent displacement of [ 11 C]-ABP688 from the mGluR5 receptors, 3–4 h 
post-administration (27%, 59%, 74%, 85% receptor occupancy for mavoglurant 25 mg, 100 mg, 200 mg, 400 mg 
dose, respectively). There were no severe adverse effects or clinically significant changes in safety parameters. 
This is the first human receptor occupancy study completed with Mavoglurant. It served to guide the dosing 
of mavoglurant in the past and currently ongoing clinical studies. Furthermore, it confirms the utility of [ 11 C]- 
ABP688 as a unique tool to study drug-induced occupancy of mGlu5 receptors in the living human brain. 
1. Introduction 
L-glutamate is a major excitatory neurotransmitter in the mam- 
malian central nervous system. Glutamate signaling involves activa- 
tion of a family of receptors including G-protein-coupled metabotropic 
receptors (mGluRs) and ionotropic glutamate receptors. mGluRs play 
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an important modulatory role in synaptic transmission, and are dis- 
tributed in various regions of the brain ( Vose and Stanton, 2017 ; 
Reiner and Levitz, 2018 ; Suh et al., 2018 ). The mGluR subtype 5 
(mGluR5), with post-synaptic expression, is found in high abundance 
in the limbic brain areas including the hippocampus, forebrain, striatal 
regions, and amygdala ( Swanson et al., 2005 ). These receptors are po- 
tentially important therapeutic targets for a number of neurological and 
therapeutic disorders including depression, fragile X syndrome (FXS), 
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anxiety, obsessive-compulsive disorders (OCD), and levodopa-induced 
dyskinesia in Parkinson’s disease (PD-LID) ( Dolen and Bear, 2008 ; 
Michalon et al., 2012 ; Akkus et al., 2014 ; Jaeschke et al., 2015 ). Ad- 
ditionally, mGluR5 antagonists have demonstrated anxiolytic actions in 
a variety of animal models, suggesting their potential to treat various 
anxiety disorders (panic disorder, social anxiety disorder, posttraumatic 
stress disorder and generalized anxiety disorder). 
Mavoglurant (AFQ056) that is developed as a structurally novel, se- 
lective, noncompetitive antagonist for mGluR5 ( Vranesic et al., 2014 ), 
has been investigated as an alternative treatment for FXS, OCD, PD-LID 
and Huntington’s disease ( Gomez-Mancilla et al., 2014 ; Reilmann et al., 
2015 ; Rutrick et al., 2017 ). It binds to the same allosteric site on mGluR5 
as [ 11 C]-ABP688, a specific radioligand developed for positron emission 
tomography (PET) imaging of the mGlu5 receptor ( Ametamey et al., 
2006 ). Successful imaging of [ 11 C]-ABP688 in the human brain has 
been demonstrated and brain kinetic data of [ 11 C]-ABP688 readily fit- 
ted to a 2-tissue compartment model, suggesting specificity in binding 
( Ametamey et al., 2007 ; Treyer et al., 2008 ). In addition, the brain ki- 
netic data were robust to noncompartmental modeling approaches such 
as Logan graphical analysis ( Treyer et al., 2007 ). 
The present study evaluates the relationship between brain mGlu5 
receptor occupancy and the extent of plasma exposure following single 
oral doses of mavoglurant using [ 11 C]-ABP688 PET imaging in healthy 
volunteers. mGlu5 receptor occupancy was also examined in various 
brain structures following single oral doses of mavoglurant. The study 
has helped to establish the binding of mavoglurant to the mGlu5 recep- 
tor in human brain in vivo, and the safety and tolerability of mavoglu- 
rant in healthy volunteers. 
2. Methods 
2.1. Study objectives 
This study assessed the extent of mGlu5 receptor occupancy follow- 
ing single oral doses of mGluR5 antagonist, mavoglurant, in the striatum 
in healthy volunteers using [ 11 C]-ABP688 PET imaging. 
2.2. Study population 
Six healthy male volunteers (aged 20–40 years) were enrolled in the 
study if they met the following eligibility criteria: male subjects in good 
health as determined by their past medical history, physical examina- 
tion, vital signs, electrocardiogram (ECG) evaluation, and laboratory 
tests at the time of screening; vital signs within normal limits and no 
evidence of postural hypotension; body weight of at least 50 kg and 
a body mass index (BMI) in the range of 19–26 kg/m 2 ; ability to pro- 
vide written informed consent before the start of any study procedures; 
ability to communicate well with the investigator and comply with the 
requirements of the study. 
All subjects enrolled in the study met the inclusion criteria at the 
screening visit and at baseline for all other treatment periods. At the 
time the study was conducted; we did not know whether subject char- 
acteristics (such as age and gender) might affect the distribution of the 
target or the pharmacokinetics of mavoglurant. We elected to restrict 
enrolment to healthy young adult males, to minimize potential between 
subject variability in a very small number of subjects. 
2.3. Study design 
This was an open-label, single-center pilot study conducted between 
04 April 2006 and 28 September 2006 at the Psychiatric University 
Clinic, University of Zurich, Switzerland. Subjects were grouped into 
two cohorts (3 per cohort) and participated in a maximum 21-day 
screening period, three study periods (Periods 1, 2 and 3), followed by 
an overnight observation, with Periods 2 and 3 approximately one week 
apart. The three successive periods comprised a baseline [ 11 C]-ABP688 
PET scan (Period 1) and [ 11 C]-ABP688 PET scans following two differ- 
ent single oral doses of mavoglurant (Periods 2 and 3). While subjects 
in cohort 1 received mavoglurant 25 mg and 200 mg doses, subjects in 
cohort 2 received mavoglurant 100 mg and 400 mg doses in Periods 2 
and 3, respectively ( Fig. 1 A). 
The final study protocol was approved by the Cantonal Ethics Com- 
mittee of Canton Zurich and Swissmedic. This study was conducted 
in accordance with International Conference on Harmonization (ICH) 
Good Clinical Practice (GCP) regulations/guidelines, and in accordance 
with the ethical principles set forth in the Declaration of Helsinki. All 
subjects provided written informed consent before the study initiation. 
2.3.1. Preparation of [ 11 C]-ABP688 
The precursor ABG018 (corresponding unsubstituted oxime of 
ABP688) was prepared by Novartis Pharma AG, Basel. The radiotracer 
[ 11 C]-ABP688 was prepared on site, at the PET Center of the University 
Hospital Zurich and the formulation for human application synthesized 
as described in Ametamey et al., 2007 . The final production of [ 11 C]- 
ABP688 was performed immediately before imaging due to the short 
half-life of 11 C (21 min). 
2.3.2. Procedures 
Subjects who were admitted to the study center on the morning of 
Day 1, Period 1, and their eligibility confirmed based on inclusion and 
exclusion criteria and baseline clinical safety data, underwent a slow 
bolus i.v. injection of the tracer with 200 MBq (207 ± 28.6 MBq, mean 
± SD) [ 11 C]-ABP688, including arterial and venous sampling ( Fig. 1 B). 
The choice of the [ 11 C]-ABP688 dose was made based on the previously 
conducted validation studies and described by Ametamey et al., 2007 , 
Treyer et al., 2007 and 2008 and to meet Swiss radiation dose limits in 
healthy subjects. 
After an interval of 1–7 days, subjects received a single dose of 25 mg 
(cohort 1) or 100 mg (cohort 2) mavoglurant in Period 2, followed by a 
PET scan with [ 11 C]-ABP688, 3 h post-drug administration, and with no 
arterial sampling. Subjects were observed for a minimum of 24 h post- 
drug administration and for another 72 h if clinically significant adverse 
events (AEs) were observed. A washout period of one week between Pe- 
riods 2 and 3 was considered due to the half-life of 15 h for mavoglurant 
( Walles et al., 2013 ). A single dose of mavoglurant 200 mg (cohort 1) 
or 400 mg (cohort 2) was administered in Period 3 followed by a PET 
scan with [ 11 C]-ABP688. Both arterial and venous sampling for plasma 
pharmacokinetics were measured in Period 3. Following each PET scan, 
subjects were observed for 24 h post-drug administration-dose ( Fig. 1 A). 
A study completion evaluation was conducted between 3 and 5 days af- 
ter receiving the last oral dose and last [ 11 C]-ABP688 PET scan. 
2.4. Imaging assessments 
High resolution T1 images (1.5 Tesla scanner, GE Healthcare, at 
the Department of Medical Radiology of the Zurich University Hospi- 
tal) were acquired for coregistration with PET scan image sets obtained 
on the Discovery-LS or Discovery-STRX PET camera (GE Healthcare) at 
Zurich University Hospital PET Center (camera of 55 cm gantry diam- 
eter, 144 mm axial field of view; image volumes consisted of 35 or 47 
slices, 4.25 mm per slice; transmission scans were obtained using low- 
dose CT scan (140 kV, 40 mA). A clinical reading was also conducted to 
ensure that participants did not have evidence of significant neurologi- 
cal disease or pathology. All calculations were performed using the ded- 
icated software PMOD (PMOD Technologies) ( Mikolajczyk et al., 1998 ). 
Decay-corrected time–activity curves were generated for the following 
cerebral regions: anterior cingulate, medial temporal lobe, parietal cor- 
tex, cerebellum, and white matter. Values for the specific distribution 
volume (DV) were calculated from the estimated rate constants. MRI 
scans were superimposed on the emission data from [ 11 C]-ABP688 PET 
scans and arterial input function were fit into compartmental (two-tissue 
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Fig. 1. A. Schematic representation of study design (whole period) B. Schematic representation of study design (single period). 
compartment) and noncompartmental (with Logan analysis) models us- 
ing PMOD to determine the model for best fit. 
2.5. Drug concentrations 
Mavoglurant concentrations in plasma were determined by a vali- 
dated LC-MS/MS method, with a lower limit of quantification (LLOQ) 
of 2 ng/mL ( Walles et al., 2013 ). 
2.6. Data analysis 
2.6.1. Model implementation 
mGlu5 receptor occupancy of single oral doses of mavoglurant was 
characterized by the EC 50 (plasma concentration for 50% max relative 
displacement and 50% receptor occupancy) of the saturable binding 
model. Two-tissue and one-tissue compartment models were compared 
to determine the best fit. The brain kinetic data were readily fit to the 
two-compartment model as the optimal model, also suggesting speci- 
ficity in binding and as demonstrated in Treyer et al., 2008 . Best fit to 
[ 11 C]-ABP688 time-activity PET data was using arterial input function 
corrected for metabolites. The estimated rate constants of the model K 1 , 
k 2 , k 3 , k 4 were used to estimate the binding potential relative to plasma 
(BP P ) ( Innis et al., 2007 ): 
𝐵 𝑃 𝑃 = 
𝐾 1 𝑘 3 
𝑘 2 𝑘 4 
= 𝑓 𝑃 
𝐵 𝑎𝑣𝑎𝑖𝑙 
𝐾 𝐷 
BP P is the binding potential relative to plasma; f P is the free fraction 
of tracer in plasma; B avail is the available receptor density. 
Displacement (D) of [ 11 C]-ABP688 by mavoglurant was calculated 
as the percent reduction from baseline in BP P measured during post- 
treatment PET scans (at scan time t). This is proportional to the percent- 
age change in receptor availability. Receptor occupancy (RO) of mGlu5 
receptors by mavoglurant was inferred from the displacement via a sat- 
uration binding equation, as described below. 
𝐷 = 1 − 𝐵 𝑃 𝑃 ( 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ) ∕ 𝐵 𝑃 𝑃 ( 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 ) 
D is the displacement; BP P is the binding potential relative to plasma 
2.6.2. Displacement versus plasma concentration 
The relationship between mavoglurant plasma concentrations and 
relative displacement of [ 11 C]-ABP688 was investigated graphically. An 
exploratory analysis was conducted to estimate the plasma concentra- 
tion associated with 50% displacement through the E max model: 
𝐷 = 
𝐸 𝑚𝑎𝑥 ∗ 𝐶 𝑝 
𝐸 𝐶 50 + 𝐶 𝑝 
D is the displacement; C p is the plasma concentration of mavoglurant 
at time t; E max is the maximum attainable displacement at very high 
plasma concentrations; EC 50 is the plasma concentration that yields 50% 
of maximum relative displacement 
2.6.3. Displacement versus dose 
In parallel to the above concentration-response analysis, a dose- 
response analysis was also conducted to estimate the dose associated 
with 50% displacement (at scan time) through the following saturation 
displacement formula: 
D = 
E max ∗ Dose 
E D 50 + Dose 
D is the displacement; dose is the dose of mavoglurant; E max is the 
maximum attainable displacement at scan time 3–4 h post-dose at very 
high doses; ED 50 is the dose that yields 50% of maximum relative dis- 
placement at scan time of 3–4 h post-dose. 
2.6.4. Receptor occupancy 
Receptor occupancy versus plasma concentration: 
Even if the receptor occupancy of mGluR5 is not directly observed, 
assuming that 100% receptor occupancy corresponds to the maximum 
displacement, then the following can be inferred: 
RO = 
C p 
E C 50 + C p 
3 
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Table 1 








200 mg Mavoglurant 400 mg 
N 5 3 4 3 








C max (ng/mL) 54.23 ± 39.09 
(39.3) 
191.6 ± 112.5 
(160.0) 
337.6 ± 217.6 
(267.0) 
1004 ± 674.1 
(837.2) 
AUC 3–4 (ng.h/mL) 31.42 ± 17.84 
(25.30) 
156.3 ± 103.7 
(130.0) 
202.8 ± 99.35 
(177.4) 
715.0 ± 429 
(597.7) 
AUC 0–12 (ng.h/mL) 200.9 ± 107.6 
(169.3) 
957.5 ± 524.8 
(823.5) 
1798 ± 946.0 
(1492) 
5054 ± 3409 
(4156) 
AUC 0–24 (ng.h/mL) 253.3 ± 143.3 
(211.5) 
1221 ± 628.5 
(1075) 
2396 ± 1210 
(1998) 
6939 ± 4946 
(5587) 
t max values presented as median (range); C max , AUC 0-t , AUC 0–12 and AUC 0–24 values represented as mean ± SD 
(geometric mean). 
Half-life of mavoglurant is estimated to be around 15 h based on previous studies ( Walles et al., 2013 ). 
RO is the receptor occupancy of mGluR5 by mavoglurant; C p is the 
plasma concentration of mavoglurant; EC 50 is again the plasma con- 
centration observed to yield 50% of maximum relative displacement; 
assumed to yield 50% RO. 
2.6.5. Receptor occupancy through the dose-response analysis 
Similarly, for the dose-response analysis, we infer receptor occu- 
pancy at scan time of 3–4 h post-dose as below: 
𝑅𝑂 = 
𝐷𝑜𝑠𝑒 
𝐸 𝐷 50 + 𝐷𝑜𝑠𝑒 
RO is the receptor occupancy of mGluR5 by mavoglurant; dose is the 
dose of mavoglurant; ED 50 is again the dose that yields 50% of maximum 
relative displacement at scan time of 3–4 h post-dose, assumed to yield 
50% RO . 
2.7. Statistical methods 
No sample size calculations were performed as this was a pilot ex- 
ploratory study with only three participants per dose group. Values of 
RO were provided by brain region relative to baseline per subject and 
listed together with the plasma PK parameters for each parameter de- 
rived from PET scans. The data were presented descriptively and no 
formal statistical comparisons were made. The relationship between ex- 
posure and occupancy at other brain regions and between mavoglurant 
plasma concentrations with the mGlu5 receptor occupancy was pre- 
sented graphically. 
3. Results 
3.1. Subject disposition and demographics 
A total of six subjects were enrolled in the study. Two of the six 
participants chose to discontinue the study for personal reasons follow- 
ing technical problems with the ABP688 bolus injection (synthesis fail- 
ure). These participants were replaced by another two subjects, both of 
whom completed the study. All eight participants enrolled were men, 
Caucasian, with mean (SD) age 27.4 (6.25) years and mean BMI 23.25 
(1.6) kg/m 2 . 
3.2. Pharmacokinetic assessments 
After administration of a single dose in healthy participants, mean 
C max and AUC values increased with dose ( Table 1 ). Onset of mavoglu- 
rant absorption was fast and no lag time was observed. Maximum con- 
centrations of mavoglurant were observed around 2–3.25 h post-dose. 
Fig. 2. Representative DV Logan images showing the effect of mavoglurant on 
binding of [ 11 C]-APB688. Normalized and averaged DV Logan images for each 
dose cohort visualize the distribution and uptake values on axial slices from 
cerebellum to cortical regions. Logan Plot method was chosen for the pixel wise 
modeling for improved image quality. DV, distribution volume. 
3.4. Analysis of receptor occupancy 
The highest distribution volume ( BP P ) of ABP668 was observed 
in the anterior cingulate region whereas the white matter and cere- 
bellum showed a low uptake ( Table 2 , Fig. 2 ). The distribution vol- 
umes ( BP P ) were in line with previously published data using ABP688 
( Ametamey et al., 2007 ) across regions. The E max model was the best 
fit to each individual region of the brain (estimates ranging from 56% 
to 72%) except to the cerebellum and white matter (outlying low E max 
estimates of 35% and 27%); these regions were not used in the analysis 
of pooled cortical areas. The displacement measured was regressed on 
doses and on plasma concentrations between 3 and 4 h after drug intake 
(time of the PET scan). 
RO 50 and E max based on plasma concentrations for each individual 
region of the brain, and for the pooled displacement across all regions 
(except cerebellum and white matter), are presented in Table 3 . 
The pooled displacement values for each individual (summing across 
all regions except cerebellum and white matter) were plotted versus 
plasma concentration using a linear concentration scale ( Fig. 3 A ) and a 
logarithmic concentration scale ( Fig. 3 B ). Assuming that the E max cor- 
responds to mGlu5 receptor occupancy of 100% and therefore, the ob- 
served EC 50 is the same for the receptor occupancy, the prediction curve 
of the RO was plotted versus the plasma concentration ( Fig. 4 A ) and the 
dose between 3 and 4 h ( Fig. 4 B ). 
The RO 50 of striatum (caudate and putamen) did not differ from 
other regions of the cerebral cortex. The E max was also similar across 
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Table 2 
Distribution volume (BP P ) and ratio k 3 /k 4 (BP ND ) per region at baseline. 
Region Distribution volume ( BP P ) Ratio K 3/ K 4 ( BP ND ) 
Anterior cingulum 5.28 (1.08) 7.1 (2.09) 
Caudate 4.99 (1.18) 7.02 (2.46) 
Cerebellum 2.01 (0.36) 2.72 (0.86) 
Frontal cortex 4.5 (1.04) 5.91 (2.05) 
Lateral temporal cortex 4.52 (1.07) 6.05 (1.92) 
Medial orbitofrontal cortex 5.24 (1.11) 7.13 (2.33) 
Mediotemporal cortex (mainly hippocampus) 5.05 (1.51) 6.62 (2.18) 
Occipitotemporal cortex 4.09 (1.07) 5.53 (1.8) 
Orbitofrontal cortex 4.39 (1.06) 5.96 (2.06) 
Parietal cortex 4.11 (0.84) 5.57 (1.82) 
Posterior cingulum 4.65 (0.96) 6.39 (2.13) 
Prefrontal cortex 4.19 (0.91) 5.53 (1.74) 
Putamen 4.75 (1.03) 6.55 (1.93) 
Thalamus 3.34 (0.62) 4.4 (1.27) 
Ventral part of anterior cingulum 5.52 (1.23) 7.43 (2.46) 
Visual cortex 3.77 (0.92) 5.12 (1.87) 
White matter 1.8 (0.45) 2.44 (0.89) 
Mean across all regions except cerebellum and white matter 5.28 (1.08) 7.1 (2.09) 
Data are expressed as mean (SD). 
BP ND , binding potential relative to the nondisplaceable compartment. 
BP P refers to the ratio at equilibrium of specifically bound radioligand to that of total parent radioligand in 
plasma (i.e., free plus protein bound, excluding radioactive metabolites). 
BP ND refers to the ratio at equilibrium of specifically bound radioligand to that of nondisplaceable radioligand 
in tissue. 
Table 3 
Estimated EC 50 and ED 50 per region of the brain. 
Region Estimated ED 50 Std. Error Estimated EC 50 Std. Error 
Anterior cingulum 65 18 43 14 
Caudate 77 21 58 20 
Cerebellum 53 53 33 33 
Frontal cortex 61 18 38 15 
Lateral temporal cortex 66 13 35 13 
Medial orbitofrontal cortex 64 16 42 14 
Mediotemporal cortex (mainly hippo) 69 18 38 17 
Occipitotemporal cortex 69 22 43 18 
Orbitofrontal cortex 71 22 36 16 
Parietal cortex 68 21 39 16 
Posterior cingulum 62 23 44 17 
Prefrontal cortex 76 21 45 17 
Putamen 68 21 50 16 
Thalamus 72 20 38 14 
Ventral part of anterior cingulum 80 23 50 18 
Visual cortex 65 27 46 21 
White matter 139 175 9 19 
Mean across all regions except cerebellum and white matter 69 24 43 20 
EC 50 is the plasma concentration (ng/mL) and ED 50 the dose which corresponds to 50% receptor occupancy. 
the cortical regions and striatum. Low E max observed in the cerebellum 
and white matter is in line with receptor distribution in humans lack- 
ing expression in these regions. The observed E max in ‘target’ regions 
(other than the white matter and cerebellum) was 65%. This suggests 
that there is still specific binding of [ 11 C]-ABP688 at high concentrations 
of mavoglurant. Estimated receptor occupancy (% occupancy) at 3–4 h 
post-dose was 27% (mavoglurant 25 mg), 59% (mavoglurant 100 mg), 
74% (mavoglurant 200 mg), and 85% (mavoglurant 400 mg) ( Fig. 3 A ). 
Across all regions except cerebellum and white matter, the ob- 
served EC 50 for AFQ056 at the mGlu5 receptor was 43 ( + /- 20) ng/mL 
( Table 3 ). A similar evaluation, regressing the displacement versus the 
dose delivered an ED 50 of 69 mg ( Table 3 ). 
4. Discussion 
The use of PET scanning with [ 11 C]-ABP688 has proved to be an 
important tool to study expression of altered mGlu5 receptors in var- 
ious developmental, psychiatric, neurodegenerative, and neurological 
disorders ( Kim et al., 2019 ; Mihov et al., 2020 ; Smart et al., 2020 ). Inte- 
grating the use of PET imaging with [ 11 C]-ABP688 to the determination 
of the relationship between receptor occupancy and the dose/blood ex- 
posure has the potential to optimize the dose finding and/or determine 
specific binding to mGlu5 receptors of noncompetitive antagonists of 
the mGlu5 receptor in humans and non-human primates ( Kagedal et al., 
2013 ; Mathews et al., 2014 ) . 
Mavoglurant was developed as a structurally novel, subtype selec- 
tive, noncompetitive antagonist at the mGlu5 receptor. It exhibits clear 
anxiolytic actions in a variety of animal models, suggesting the poten- 
tial to treat various anxiety disorders including panic disorder, social 
anxiety disorder, posttraumatic stress disorder and generalized anxiety 
disorder. The results of the present study and the human PK profile of 
mavoglurant ( Walles et al., 2013 ) were key to guide the choice of dose 
and regimen used in the clinical trials conducted with mavoglurant. lack 
of efficacy reported in obsessive compulsive disorders ( Rutrick et al., 
2017 ). Although, the dosing and regimen used in the Huntington’s 
disease ( Reilmann et al., 2015 ), the obsessive compulsive disorders 
( Rutrick et al., 2017 ) and Fragile X (adults and adolescents) studies was 
such that it resulted in 80% receptor occupancy, this did not result in 
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Fig. 3. Displacement vs blood concentrations 
Relative displacement versus blood concentrations (ng/mL) at 3–4 h post dose. A. Linear concentration scale B. Logarithmic concentration scale. Data comprised 
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Fig. 4. Estimated receptor occupancy versus dose and blood concentration 
A. Estimated receptor occupancy versus blood concentrations (ng/mL) B. Estimated receptor occupancy at 3–4 h post dose versus dose. 
efficacy during the treatment period. Similarly for FXS, another selec- 
tive mGluR5 antagonist (basimglurant) did not achieve efficacy while 
achieving sufficient receptor occupancy ( Quiroz et al., 2016 ). Taken to- 
gether, these results indicate that mGluR5 antagonists might not be a 
therapeutic option for these pathologies. 
The situation appears to be different in Parkinson’s disease where 
mavoglurant demonstrated efficacy in reducing l -Dopa induced dyski- 
nesia in two proof of principle trials (150 mg b.i.d.; Berg et al., 2011 ) 
and at the highest dose (100 mg b.i.d.) in a phase IIb trial; Stocchi et al., 
2013 ). In contrast, no efficacy could be demonstrated in other trials 
(100, 150, 200 mg b.i.d.; Trenkwalder et al., 2016 ). 
Mavoglurant binds to all mGlu5 receptors in brain regions of 
interest. Mavoglurant passes the blood–brain barrier and induces 
a dose/exposure-dependent displacement of [ 11 C]-ABP688 bound to 
mGlu5 receptors in humans in vivo. The study procedures for safety 
and blood sampling were well tolerated with no serious AEs or dropouts 
due to AEs. PET and [ 11 C]-ABP688 provide a unique tool to study drug- 
induced occupancy of mGlu5 receptors in the brain. 
The distribution volumes of mavoglurant agree well with previously 
published data, with the highest distribution volumes observed in the 
cingulate region ( Ametamey et al., 2007 ). Relatively lower uptake is ob- 
served in the nontarget regions, cerebellum and white matter, possibly 
due to the presence of myelinated axonal sheets that are likely devoid of 
mGlu5 receptors and sheathed from drug absorption. Mavoglurant binds 
to mGluR5 receptor thus blocking [ 11 C]-ABP688 from cortical receptor 
regions of interest. A single oral dose of 400 mg induced an estimated 
displacement of 63% at scan time of 3–4 h post-dose, inferring a receptor 
occupancy estimate of nearly 85%. 
Despite many studies involving the mGlu5 receptor in various dis- 
orders, this receptor and its interactions are yet to be fully understood 
before its application as a therapeutic target. 
5. Conclusion 
The results of this study clearly demonstrate that Mavoglurant pen- 
etrates the brain and dose/exposure dependently prevents the binding 
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of [ 11 C]-ABP688 from the mGlu5 receptors in humans in vivo. In ad- 
dition, mavoglurant binds evenly to all mGlu5 receptor brain regions 
of interest. The results of this study have been of key importance in 
determining the clinical doses of mavoglurant in the conducted clini- 
cal trials. The study shows that [ 11 C]-ABP688 PET imaging provides a 
unique tool to study drug-induced occupancy of mGlu5 receptors in the 
living human brain. 
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